Home / Market Reports / Medical Care
/ Global Next Generation Antibody Therapeutics Market Growth (Status and Outlook) 2025-2031
Global Next Generation Antibody Therapeutics Market Growth (Status and Outlook) 2025-2031
-
PDF DOWNLOAD
GET FREE SAMPLE
CUSTOMIZE REQUEST
PDF DOWNLOAD
GET FREE SAMPLE
CUSTOMIZE REQUEST
Provide comprehensive and accurate analysis and reports according to your exact requirements
The global Next Generation Antibody Therapeutics market size is predicted to grow from US$ 14310 million in 2025 to US$ 44360 million in 2031; it is expected to grow at a CAGR of 20.7% from 2025 to 2031.
Building on the huge success of monoclonal antibody therapeutics, the next generation of antibody-based products such as Antibody Drug Conjugate (ADC) and Bispecific Antibody (BsAb) is now opening up new opportunities.
The global next-generation antibody therapeutics market is expected to grow significantly over the next decade, driven by the increasing prevalence of cancer, autoimmune diseases, and infectious diseases, along with advancements in biotechnology. Oncology will remain the largest segment, but there will be strong growth in autoimmune diseases, infectious diseases, and neurological conditions.
In conclusion, technological advancements, regulatory support, and the increasing use of antibodies in combination therapies will continue to fuel the market's growth, making next-gen antibody therapeutics one of the most promising areas in biopharmaceutical innovation.Global key players of next generation antibody therapeutics include Roche, Seagen, Amgen, Pfizer, Takeda, etc. The top two players hold a share over 70%. North America is the largest market, has a share about 65%, followed by Europe and Asia-Pacific, with share 16% and 15%, separately. In terms of product type, Antibody Drug Conjugate (ADC) is the largest segment, occupied for a share of 60%, and in terms of application, Cancer has a share about 66 %.
LPI (LP Information)' newest research report, the “Next Generation Antibody Therapeutics Industry Forecast” looks at past sales and reviews total world Next Generation Antibody Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Next Generation Antibody Therapeutics sales for 2025 through 2031. With Next Generation Antibody Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Next Generation Antibody Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Next Generation Antibody Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Next Generation Antibody Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Next Generation Antibody Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Next Generation Antibody Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Next Generation Antibody Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Next Generation Antibody Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Antibody Drug Conjugate (ADC)
Bispecific Antibody (BsAb)
Segmentation by Application:
Cancer
Haemophilia
Other Non-Cancer Diseases
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Amgen
Pfizer
Takeda
Daiichi Sankyo
Seagen
Astellas
Immunomedics
GSK
Immunocore
ADC Therapeutics